Trial Profile
The Efficacy and Safety of CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma: a Randomized, Double-blind, Double Dummy, Multicenter Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Vorolanib (Primary) ; Everolimus
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms CONCEPT
- Sponsors AnewPharma
- 07 Feb 2023 According to ClinicalTrials.gov record, the recruitment status of this study is unknown because the information has not been verified recently (last verified February 2021 ).
- 01 Nov 2022 Results assessing the combination of vorolanib and everolimus or vorolanib alone versus a control arm of everolimus as second-line treatment in patients with metastatic renal cell carcinoma , published in the European Journal of Cancer
- 08 Jun 2021 Primary endpoint (Progression-free survival) has been met as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.